Neurocrine Biosciences

Neurocrine Biosciences is a biopharmaceutical company headquartered in San Diego, California that develops and commercializes treatments for neurological, endocrine, psychiatric, and immunological disorders. Its approved products include Ingrezza for tardive dyskinesia and Huntington's disease chorea, and Crenessity for congenital adrenal hyperplasia, alongside an active clinical pipeline. The company is publicly traded on Nasdaq under the ticker NBIX and was founded in 1992.